Novel Autotaxin Inhibitors



Challenge

- Autotaxin (ATX) is an essential human enzyme, primarily known for the formation of lysophosphatidic acid (LPA). The ATX-LPA axis is linked to numerous physiological and pathological processes such as vascular and neuronal development, multiple sclerosis, atherosclerosis and cancer, making ATX a promising therapeutic target.
- Despite huge needs and efforts, no ATX inhibitor has reached the market yet.

Comprehensive characterization

- Chemical (e.g. synthesis examples)
- NMR/Mass spectrometry analysis
- Biochemical (dose response and mode of inhibition assay, FS3 Autotaxin activity assay)
- Structural (co-crystal structure of the compound and hATX)
- Cellular assay (hLPAR1 internalization assay, cytotoxicity assay)

https://pixabay.com/de/illustrations/dimethoxyphenet hylamin-dopamin-867172/

Technology

- Novel set of ATX inhibitors
- One compound developed further and characterized comprehensively:

Better chemical properties and different mechanism of action make conceivable:

- Huge range of <u>application scenarios</u> (e.g. prophylactic, therapeutic and diagnostic)
- Different <u>administration routes (e.g. oral, rectal)</u>
- Specific adaptation to a <u>large spectrum of</u> <u>disorders</u> (e.g. inflammatory diseases, neurodegenerative diseases, cancer).
 - Two druggable scaffolds
 - Increased noncompetitive inhibitory activity towards ATX.

non- Alliance autotax ve inhibitory signalin wards ATX

Intellectual Property

A priority patent application has been filed.

Commercial Opportunity

The technology is comprehensively evaluated in vitro and available for out-licensing or co-development. We also offer a technology evaluation program.

Further Reading

Eymery et al. 2023, Life Science Alliance: Medicinal cannabis & autotaxin–lysophosphatidic acid signaling



EMBLEM TECHNOLOGY TRANSFER GMBH

- O Boxbergring 107
 - D-69126 Heidelberg

Germany

- ≫ Tel.: +49 (0) 6221 363 22 10
- info@embl-em.de
- www.embl-em.de
- Dr. Jürgen Bauer bauer@embl-em.de

 Diminished side effects expected

 No toxicity towards human cells

Internal Reference

2022-022

Key Inventors

Mathias Eymery, EMBL Grenoble, France

Andrew McCarthy, EMBL Grenoble, France